NCT01845844 - Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Diabetic Macular Edema

Interventions

DRUG

Ranibizumab 0.3mg/0.05cc

"Group A (Arm A) will receive monthly 0.3mg/0.05cc intravitreal injections for 12 consecutive months.~Group B (Arm B) will receive monthly 0.3mg/0.05cc intravitreal injections for the first six months and then PRN for the remaining 6 months per protocol specified criteria."

Trial Locations (1)

30909

RECRUITING

Southeast Retina Center, PC, Augusta